Syndax Pharmaceuticals (SNDX) Enterprise Value (2016 - 2026)

Syndax Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$352.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 122.67% year-over-year to -$352.1 million; the TTM figure through Mar 2026 stood at -$352.1 million (down 122.67% YoY), while the FY2025 annual figure was -$154.5 million, up 5.83% from the prior year.
• Enterprise Value for Q1 2026 stood at -$352.1 million, down from -$154.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$63.3 million in Q1 2023, with the low at -$570.7 million in Q4 2023.
• The 5-year median for Enterprise Value is -$158.1 million (2025), against an average of -$251.0 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 84.09% in 2023, then plunged 586.22% in 2024.
• Syndax Pharmaceuticals' Enterprise Value stood at -$475.8 million in 2022, then fell by 19.94% to -$570.7 million in 2023, then jumped by 71.24% to -$164.1 million in 2024, then rose by 5.83% to -$154.5 million in 2025, then plunged by 127.81% to -$352.1 million in 2026.
• Business Quant data shows SNDX's Enterprise Value at -$352.1 million in Q1 2026, -$154.5 million in Q4 2025, and -$135.0 million in Q3 2025.